CR Double-Crane Posts Softer Q1 Earnings but Stronger Cash Position for 2026

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an update.

China Resources Pharmaceutical Group has disclosed the unaudited first-quarter 2026 financial results of its Shanghai-listed subsidiary, China Resources Double-Crane, which remain subject to potential audit adjustments and do not represent the consolidated position of the wider group. The update shows that while Double-Crane’s revenue and net profit both declined slightly year on year, its total assets, liabilities and owners’ equity increased, and it generated a sharp rise in net cash inflow, signaling improved liquidity despite softer top-line performance.

For the three months ended 31 March 2026, CR Double-Crane reported revenue of RMB 2.81 billion versus RMB 3.08 billion a year earlier, and net profit of RMB 501 million compared with RMB 523 million, reflecting modest pressure on sales and earnings. However, net cash from operations surged to about RMB 658 million from RMB 272 million, and period-end cash stood at RMB 2.57 billion, suggesting stronger cash management and a solid balance sheet, though investors are cautioned not to rely solely on this subsidiary data when assessing the group’s overall financial health.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Ltd. is a Hong Kong–incorporated pharmaceutical group that controls a 60.25% stake in China Resources Double-Crane Pharmaceutical Co., Ltd., a drug manufacturer listed on the Shanghai Stock Exchange. Through CR Double-Crane, the group operates across the Chinese pharmaceutical market, focusing on the production and sale of medicines and related healthcare products.

Average Trading Volume: 18,740,562

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$36.69B

See more data about 3320 stock on TipRanks’ Stock Analysis page.